Wisp, Visby Partner to Expand Access to At-Home STI Test

Why It Matters

By linking rapid at‑home diagnostics with immediate telehealth treatment, the partnership speeds care delivery and could lower STI‑related infertility rates, showcasing a scalable model for integrated women’s health services.

Key Takeaways

• Visby’s at‑home PCR test delivers results in 30 minutes via app
• Test costs $149.99, eligible for FSA/HSA reimbursement
• Wisp provides free virtual follow‑up care and prescription delivery
• Partnership targets reducing STI‑related infertility by speeding treatment
• FDA‑authorized test expands accessible women’s sexual health services

Pulse Analysis

The United States sees roughly 100,000 cases of infertility each year linked to untreated sexually transmitted infections, while globally more than one million curable STIs are contracted daily. Traditional clinic‑based testing often creates delays, especially for asymptomatic patients who may never seek care. At‑home polymerase chain reaction (PCR) kits have emerged as a disruptive alternative, offering laboratory‑grade accuracy without the need for a physical visit. Visby Medical’s palm‑sized test, FDA‑authorized and capable of delivering results in 30 minutes through a mobile app, exemplifies this shift toward rapid, consumer‑driven diagnostics.

The new alliance between Wisp, a women‑focused telehealth platform, and Visby bridges the diagnostic gap by coupling instant results with immediate clinical follow‑up. When a user receives a positive chlamydia, gonorrhea or trichomoniasis result, Wisp automatically offers a virtual consultation at no extra charge, enabling a licensed provider to prescribe antibiotics that are shipped directly to the patient’s door. This end‑to‑end workflow eliminates the typical friction of scheduling appointments, insurance paperwork, and pharmacy trips, thereby increasing treatment adherence and reducing the window for disease progression.

Beyond the direct health benefits, the partnership signals a broader market trend where digital health companies are bundling testing and treatment to create fully integrated care pathways. The $149.99 price point, eligible for Flexible Spending Accounts and Health Savings Accounts, makes the service financially accessible to a wide demographic. As insurers and employers prioritize cost‑effective preventive care, models like Wisp‑Visby are likely to attract reimbursement support and inspire similar collaborations across other therapeutic areas, reshaping how women’s sexual health is delivered in the United States.